ClinicalTrials.gg
CompletedNCT02242318Updated Sep 17, 2014

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

A Phase 4 interventional study of Telmisartan and Valsartan in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
30th of 99
440 · median 184
Started
2001
with 3 others
Phase 4
32 of 99
1 open now
Registered
69th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 30th largest by enrollment, is one of 4 that started in 2001, is one of 32 in phase 4, and was the 69th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over 24 hours), and to compare telmisartan 80 mg to valsartan 160 mg in lowering DBP during the last six hours of the dosing interval at the end of a 6 to 8-week treatment period, as measured by ABPM (change from baseline)

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, at Visit 2
  2. 24-hour mean DBP of ≥ 85 mmHg at Visit 3 as measured by ABPM
  3. Age 18 years or older
  4. Ability to stop any current antihypertensive therapy without risk to the patient (investigator's discretion)
  5. Patient's written in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  1. Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who

    1. are not surgically sterile,
    2. are nursing,
    3. are of and are NOT practising acceptable methods of , or do NOT plan to continue practising an acceptable method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives and Intra Uterine Devices (IUD)
  2. Known or suspected secondary hypertension
  3. Mean sitting SBP ≥180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the placebo run-in period
  4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    1. Serum Glutamate-Pyruvate-Transaminase () (SGPT (ALT)) or Serum Glutamate-Oxaloacetate-Transaminase (Aspartate Aminotransferase) (SGOT (AST)) > than 2 times the ,
    2. Serum creatinine > 2.3 mg/dL (or > 203 μmol/l)
  5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients postrenal transplant or with only one kidney
  6. sodium depletion, hypokalaemia or hyperkalaemia
  7. Uncorrected volume depletion
  8. Primary aldosteronism
  9. Hereditary fructose intolerance
  10. Biliary obstructive disorders
  11. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
  12. History of drug or alcohol dependency within six months prior to start of run-in period
  13. Concomitant administration of any medications known to affect blood pressure, except medication allowed by the protocol
  14. Any therapy within one month of signing the form
  15. Congestive heart failure ( (NYHA) functional class Congestive Heart Failure (CHF III-IV))
  16. Unstable angina within the past three months prior to start of run-in period
  17. Stroke within the past six months prior to start of run-in period
  18. Myocardial infarction or cardiac surgery within the past three months prior to start of run-in period
  19. Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past three months prior to start of run-in period
  20. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  21. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  22. Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an ≥ 10%
  23. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 Ante Meridiem (AM)
  24. Known to any component of the formulations
  25. Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication
  26. Inability to comply with the protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Telmisartan

    low dose for two weeks, then up titration to high dose, once daily

    Drug: Telmisartan · Drug: Placebo

  • Active comparator
    Valsartan

    low dose for two weeks, then up titration to high dose, once daily

    Drug: Valsartan · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose

    measured by ambulatory blood pressure monitoring (ABPM)

    Time frame: Baseline, Day 41, Day 55

  2. Change in mean DBP during the last 6 hours of the 24 hour dosing interval

    Time frame: up to 8 weeks

Secondary outcomes

  1. Change in 24-hour mean systolic blood pressure (SBP) after a missed dose

    Time frame: Baseline, Day 41, Day 55

  2. Change in mean SBP during the last 6 hours of the 24-hour dosing interval

    Time frame: up to 8 weeks

  3. Change in pulse pressure (PP)

    Time frame: up to 8 weeks

  4. Change in 24-hour mean DBP after an active dose of study medication

    Time frame: up to 8 weeks

  5. Change in 24-hour mean SBP after an active dose of study medication

    Time frame: up to 8 weeks

  6. Change in mean seated trough SBP/DBP/PP in- clinic manual cuff sphygmomanometer after a missed dose

    Time frame: up to 8 weeks

  7. Change in the mean seated trough SBP/DBP/PP in- clinic manual cuff sphygmomanometer after an active dose of study medication

    Time frame: up to 8 weeks

  8. Responder rate measured by ABPM after a missed dose of study medication

    * ABPM DBP "control" (24-hour mean DBP \< 80 mmHg), * ABPM DBP "response" (24-hour mean DBP \< 80 mmHg and/or reduction from baseline ≥ 10 mmHg), * ABPM SBP "response" (24-hour mean SBP \< 130 mmHg and/or reduction from baseline ≥ 10 mmHg)

    Time frame: Baseline, Day 41, Day 55

  9. Responder rate measured by ABPM after an active dose of study medication

    * ABPM DBP "control" (24-hour mean DBP \< 80 mmHg), * ABPM DBP "response" (24-hour mean DBP \< 80 mmHg and/or reduction from baseline ≥ 10 mmHg), * ABPM SBP "response" (24-hour mean SBP \< 130 mmHg and/or reduction from baseline ≥ 10 mmHg)

    Time frame: up to 8 weeks

  10. Responder rate in- clinic manual trough cuff measurements after a missed dose of study medication

    * DBP "control" (DBP \< 90 mmHg), * DBP "response" (DBP \< 90 mmHg and/or fall of ≥ 10 mmHg), * SBP "response" (SBP \< 140 mmHg and/or fall of ≥ 10 mmHg), * BP "normal" (SBP \< 130 mmHg and DBP \< 85 mmHg), * BP "normal / high normal" (SBP \< 140 mmHg and DBP \< 90 mmHg).

    Time frame: Baseline, Day 41, Day 55

  11. Responder rate in- clinic manual trough cuff measurements after an active dose of study medication

    * DBP "control" (DBP \< 90 mmHg), * DBP "response" (DBP \< 90 mmHg and/or fall of ≥ 10 mmHg), * SBP "response" (SBP \< 140 mmHg and/or fall of ≥ 10 mmHg), * BP "normal" (SBP \< 130 mmHg and DBP \< 85 mmHg), * BP "normal / high normal" (SBP \< 140 mmHg and DBP \< 90 mmHg).

    Time frame: up to 8 weeks

  12. Number of patients with adverse events

    Time frame: up to 8 weeks

  13. Change in 24-hour Pulse Pressure (PP) after a missed dose

    Time frame: Baseline, Day 41, Day 55

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001 and a primary completion of Sep 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 17, 2014
Start
Sep 2001
Primary completionActual
Sep 2002
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02242318
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Sep 2001
Primary completion
Sep 2002
Last update
Sep 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion